We often remark that industry ceo's need to get out more and explain themselves to the public. However, the notion still seems to stop with shareholders who, of course, are a vital constituency. Ironically, though, Jeff talks to Bloomberg TV about the need to explain high prices, but he really ought to start making this case to consumers. And he needs to elaborate...
"We've tried to dismantle this monolithic structure of R&D and create smaller therapeutic areas,'' Kindler says. "There absolutely needs to be more efficiencies in research and development across the industry, and Pfizer is no exception.''
"It is all about leadership,'' Kindler says. "I am not a scientist; I don't pretend to be a scientist. My father was a doctor and that's as close as I'll ever get to being a doctor. But I've learned to ask questions and listen.''
"The vast majority of drugs in the world were created by the private, innovative pharmaceutical industry. We have to do a better job of explaining that to people,'' Kindler says. "When it comes to their health and money, a lot of people are frustrated about the prices and the fact that we make money. We at Pfizer are doing everything we can to improve that...We are in a business that is about making money and returns for shareholders, and that is the only way we can innovate.''